Current diagnostic tests cannot reliably determine prostate cancer extent (volume and location) or biological aggressiveness. Our long term goal is to develop a non-invasive imaging technique that accurately assesses the clinical significance of prostate cancer and that can be used for diagnosis, treatment planning, and therapeutic monitoring. The main objective of this particular application is to realize the full potential of 3 Tesla MRI to generate cancer probability maps by combining the multi-parametric data generated from anatomic and functional studies within a new statistical model. Therefore, based on previous results from our group and others, the central hypothesis is that multi-parametric anatomic, vascular and metabolic data can determine the extent and aggressiveness of prostate cancer as validated by correlation with postoperative histopathologic determination of extent and tumor grade, and molecular assessment of aggressiveness. Supported by previous developments, this hypothesis will be tested with four specific aims: 1) generate parametric maps from MRI data acquired and processed with novel techniques;2) develop and validate a 3-dimensional (3D) strategy to spatially co-register MRI images to histopathology sections from prostatectomy;3) develop a classifier based on 3T MRI data to produce a 3D probability map of cancer;and 4) identify MRI features that predict histological and molecular markers of aggressiveness. Under the first two aims MRI data will be acquired and processed with developed methods to generate improved parametric maps which are then registered to reconstructed histopathology volumes. Under the third aim, the MRI parametric maps and histopathology results are used to train a statistical classifier to facilitate the generation of patient specific cancer probability maps. Finally, in the fourth aim, proven molecular markers of aggressiveness will be correlated with MRI, histopathology and standard clinical factors. The proposed work is innovative in several ways: 1) it will implement new acquisition and quantitation methods for DCE-MRI and 3DSI on a 3 Tesla system;2) it will use novel and robust statistical modeling to simultaneously combine anatomic and MRI data to determine the extent of cancer, and 3) it will correlate MRI features with spatially registered histopathology and proven aggressiveness biomarkers. Our expected outcome is the development of a novel MRI-based imaging method to non-invasively and reliably determine both the extent and aggressiveness of prostate cancer. It is our hope that the methods developed in this study may permit doctors and their patients to make better treatment decisions and reduce morbidity and mortality due to prostate cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
3R01CA131013-02S1
Application #
7847989
Study Section
Biomedical Imaging Technology Study Section (BMIT)
Program Officer
Zhang, Huiming
Project Start
2009-06-01
Project End
2011-09-30
Budget Start
2009-06-01
Budget End
2011-09-30
Support Year
2
Fiscal Year
2009
Total Cost
$50,410
Indirect Cost
Name
University of Minnesota Twin Cities
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
555917996
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Metzger, Gregory J; Kalavagunta, Chaitanya; Spilseth, Benjamin et al. (2016) Detection of Prostate Cancer: Quantitative Multiparametric MR Imaging Models Developed Using Registered Correlative Histopathology. Radiology 279:805-16
Ertürk, M Arcan; Tian, Jinfeng; Van de Moortele, Pierre-François et al. (2016) Development and evaluation of a multichannel endorectal RF coil for prostate MRI at 7T in combination with an external surface array. J Magn Reson Imaging 43:1279-87
Kalavagunta, Chaitanya; Zhou, Xiangmin; Schmechel, Stephen C et al. (2015) Registration of in vivo prostate MRI and pseudo-whole mount histology using Local Affine Transformations guided by Internal Structures (LATIS). J Magn Reson Imaging 41:1104-14
Wasserman, Neil F; Spilseth, Benjamin; Golzarian, Jafar et al. (2015) Use of MRI for Lobar Classification of Benign Prostatic Hyperplasia: Potential Phenotypic Biomarkers for Research on Treatment Strategies. AJR Am J Roentgenol 205:564-71
Kalavagunta, Chaitanya; Michaeli, Shalom; Metzger, Gregory J (2014) In vitro Gd-DTPA relaxometry studies in oxygenated venous human blood and aqueous solution at 3 and 7?T. Contrast Media Mol Imaging 9:169-76
Rizzardi, Anthony E; Rosener, Nikolaus K; Koopmeiners, Joseph S et al. (2014) Evaluation of protein biomarkers of prostate cancer aggressiveness. BMC Cancer 14:244
Rizzardi, Anthony E; Vogel, Rachel Isaksson; Koopmeiners, Joseph S et al. (2014) Elevated hyaluronan and hyaluronan-mediated motility receptor are associated with biochemical failure in patients with intermediate-grade prostate tumors. Cancer 120:1800-9
Li, Xiufeng; Metzger, Gregory J (2013) Feasibility of measuring prostate perfusion with arterial spin labeling. NMR Biomed 26:51-7
Koopmeiners, Joseph S; Vogel, Rachel Isaksson (2013) Early termination of a two-stage study to develop and validate a panel of biomarkers. Stat Med 32:1027-37
Rizzardi, Anthony E; Johnson, Arthur T; Vogel, Rachel Isaksson et al. (2012) Quantitative comparison of immunohistochemical staining measured by digital image analysis versus pathologist visual scoring. Diagn Pathol 7:42

Showing the most recent 10 out of 13 publications